**2021 ICD-O-3.2 UPDATE**

**TABLES 1-5**

**Table 1: New behavior codes (Reportable neoplasms)**

WHO has changed behavior codes for the following terms which result in previously non-reportable neoplasms becoming reportable for cases diagnosed 1/1/2021 forward. DO NOT report cases diagnosed prior to 1/1/2021.

|  |  |  |  |
| --- | --- | --- | --- |
| **Action** | **ICD-O**  **Code** | **Term/Site** | **Comments** |
| New behavior | 8077/2 | Squamous intraepithelial neoplasia, grade II | Change from /0 **Excludes cervix**  Refer to standard setter and/or state guidelines for further reportability guidelines |
| New behavior | 8150/3 | Pancreatic endocrine tumor, NOS (C25.4)  Islet cell adenoma (C25.4)  Islet cell adenomatosis (C25.4)  Nesidioblastoma (C25.4)  Islet cell tumor, NOS (C25.4) | Change from /1  Change from /0  Change from /0  Change from /0  Change from /1 |
| New behavior | 8151/3 | Insulinoma, NOS (C25.4)  Beta cell adenoma (C25.4) | Change from /0  Change from /0 |
| New behavior | 8158/3 | ACTH-producing tumor  Endocrine tumor, functioning, NOS | Change from /1 |
| New behavior code and term | 8380/2 | Endometrioid intraepithelial neoplasia (C54.1) |  |
| New behavior code | 8408/3 | Aggressive digital papillary adenoma (C44. \_) | Change from behavior /1 |
| New behavior/term | 8452/3 | Solid pseudopapillary neoplasm of pancreas | Change from /1 |
| New behavior code and term | 8620/3 | Granulosa cell tumor, adult type (C56.9) | Reportable for cases diagnosed 1/1/2021 forward |
| New behavior/term | 8690/3 | **Middle ear paraganglioma (C30.1, C755.5))**  Glomus jugulare tumor, NOS (C75.5)  Jugular paraganglioma C75.5)  Jugulotympanic paraganglioma (C75.5) | Change from /1 |
| New behavior code | 8691/3 | **Aortic body tumor (C75.5)**  Aortic body paraganglioma (75.5)  Aorticopulmonary paraganglioma (C75.5) | Change form /1 |
| New behavior/term | 8692/3 | **Carotid body paraganglioma (C75.4)**  Carotid body tumor (75.4) | Change from /1 |
| New behavior code | 8693/3 | **Extra-adrenal paraganglioma, NOS**  Nonchromaffin paraganglioma, NOS  Chemodectoma  Composite paraganglioma  Laryngeal paraganglioma  Vagal paraganglioma | Change from /1 |
| New behavior | 8700/3 | **Pheochromocytoma, NOS (74.1)**  Adrenal medullary paraganglioma (74.1)  Chromaffin paraganglioma (C74.1)  Chromaffin tumor  Chromaffinoma  Composite pheochromocytoma (C74.1)  Pheochromoblastoma C74.1) | Change from /0 |
| New behavior code | 8936/3 | Gastrointestinal autonomic nerve tumor  GANT  Gastrointestinal pacemaker cell tumor | Change from /1 |
| New behavior/term | 9505/0 | Multinodular and vascolating neuronal tumor (MVNT) (C71.2) |  |
| New behavior/term | 9766/3 | Lymphomatoid granulomatosis, grade 3 |  |

**Table 2: New behavior codes (Non-reportable neoplasms)**

WHO has changed behavior codes for the following terms which result in reportable neoplasms becoming non-reportable beginning with cases diagnosed 1/1/2021. Continue reporting these cases when diagnosed prior to 1/1/2021.

|  |  |  |  |
| --- | --- | --- | --- |
| **Action** | **ICD-O**  **Code** | **Term/Site** | **Comments** |
| New behavior | 8832/1 | Dermatofibrosarcoma protuberans, NOS (C44. \_)  Dermatofibrosarcoma, NOS (C44. \_) | Change from /3 |
| New behavior | 8833/1 | Pigmented dermatofibrosarcoma protuberans  (C44. \_)  Bednar tumor (C44. \_) | Change from /3 |
| New behavior code (***for specific sites only)*** | 9080/1 | Immature teratoma of the lung (C34. \_)  Immature teratoma of thymus (C37.9)  Immature teratoma of thyroid (C73.9) | Change from behavior /3 for the histology/site combination will make these terms non-reportable |
| New behavior code | 9709/1 | Primary cutaneous CD4-positive small/medium T-cell lymphoma (C44. \_) | Change from /3 |
| New behavior code | 9718/1 | Primary cutaneous CD30+ T cell lymphoproliferative disorder (C44. \_)  Lymphoid papulosis (C44. \_) | Change for /3 |
| New behavior/term | 9725/1 | Hydroa vacciniforme-like lymphoproliferative disorder | Change from /3. |
| New behavior code | 9751/1 | Langerhans cell histiocytosis, NOS  Langerhans cell histiocytosis, monostotic  Langerhans cell histiocytosis, polystotic | Change from /3 |
| New behavior | 9971/1 | Polymorphic Post Transplant Lymphoproliferative Disorder (PTLD) | Change from /3 |
| New behavior & term | 8335/1 | Follicular tumor of uncertain malignant potential (C73.0) Preferred term  Follicular carcinoma, encapsulated (C73.9) | Change from /3 |

**Table 3: Deleted ICD-O codes in ICD-O-3.2**

Per ICD-O-3.2, several ICD-O codes have been removed and the histologies moved to other codes. The comment column provides coding instructions for cases diagnosed prior to 1/1/2021 and 1/1/2021 forward. This table lists only ***reportable*** neoplasms.

|  |  |  |  |
| --- | --- | --- | --- |
| **ICD-O-3/3.1**  **Code/behavior** | **Term(s)** | **ICD-O-3.2 code**  **(1/1/2021)** | **Comments** |
| 8471/3 | Papillary mucinous cystadenocarcinoma (C56.9)  Papillary pseudomucinous cystadenocarcinoma (C56.9) | 8470/3 | Cases diagnosed ***prior*** to 1/1/2021 use code 8471/3  Cases diagnosed 1/1/2021 forward use code 8470/3 |
| 9150/3 | Hemangiopericytoma, malignant | 8815/3 | Cases diagnosed ***prior*** to 1/1/2021 use code 9150/3  Cases diagnosed 1/1/2021 forward use code 8815/3 |
| 9260/3 | Ewing sarcoma | 9364/3 | 1/1/2021 forward Ewing sarcoma is the preferred term for 9364/3 and is no longer coded to 9260/3. Cases DX’d prior to 1/1/2021 should be coded to 9260/3 |
| 9670/3 | Malignant lymphoma, small B lymphocytic, NOS *(see also M-*  *9823/3)*  Malignant lymphoma, lymphocytic, diffuse, NOS  Malignant lymphoma, lymphocytic, NOS  Malignant lymphoma, lymphocytic, well differentiated, diffuse  Malignant lymphoma, small cell diffuse  Malignant lymphoma, small cell, NOS  Malignant lymphoma, small lymphocytic, diffuse  Malignant lymphoma, small lymphocytic, NOS | 9823/3 | Cases diagnosed ***prior*** to 1/1/2021 use code 9670/3  Cases diagnosed 1/1/2021 forward use code 9823/3 |
| 9728/3 | Precursor B-cell lymphoblastic lymphoma *(see also M-*  *9836/3)* | 9811/3 | Cases diagnosed ***prior*** to 1/1/2021 use code 9728/3  Cases diagnosed 1/1/2021 forward use code 9811/3 |
| 9729/3 | Precursor T-cell lymphoblastic lymphoma *(see also M-*  *9837/3)* | 9837/3 | Cases diagnosed ***prior*** to 1/1/2021 use code 9729/3  Cases diagnosed 1/1/2021 forward use code 9837/3 |
| 9826/3 | Burkitt cell leukemia *(see also M-9687/3)*  Acute leukemia, Burkitt type [obs]  Acute lymphoblastic leukemia, mature B-cell type  B-ALL [obs]  FAB L3 [obs] | 9687/3 | Cases diagnosed ***prior*** to 1/1/2021 use code 9826/3  Cases diagnosed 1/1/2021 forward use code 9687/3 |
| 9836/3 | Precursor B-cell lymphoblastic leukemia *(see also M-9728/3)*  c-ALL  Common ALL  Common precursor B ALL  Pre-B ALL  Pre-pre-B ALL  Pro-B ALL | 9811/3 | Cases diagnosed ***prior*** to 1/1/2021 use code 9836/3  Cases diagnosed 1/1/2021 forward use code 9811/3 |
| 9991/3 | Refractory neutropenia | 9980/3 | Cases diagnosed ***prior*** to 1/1/2021 use code 9991/3  Cases diagnosed 1/1/2021 forward use code 9980/3 |
| 9992/3 | Refractory thrombocytopenia | 9980/3 | Cases diagnosed ***prior*** to 1/1/2021 use code 9992/3  Cases diagnosed 1/1/2021 forward use code 9980/3 |

**Table 4: Changes in reportable terminology**

**(\*)** WHO has revised preferred terminology for these neoplasms and no longer requires “malignant” to be used in the term in order to code behavior of /3

|  |  |  |  |
| --- | --- | --- | --- |
| **Action** | **ICD-O**  **Code** | **Term/Site** | **Comments** |
| New term | 8151/3 | Insulinoma | **(\*)** |
| New term | 8152/3 | Glucagonoma | **(\*)** |
| New term | 8153/3 | Gastrinoma | **(\*)** |
| New term | 8155/3 | VIPoma | **(\*)** |
| New term | 8156/3 | Somatostatinoma | **(\*)** |
| New term | 8580/3 | Thymoma, NOS (C37.9)  Metaplastic thymoma **(C37.9)**  Sclerosing thymoma (C34. \_)  Intrapulmonary thymoma C34. \_) | **(\*)** |
| New term | 8581/3 | Type A thymoma including atypical variant **(C37.9)** | **(\*)** |
| New term | 8582/3 | Type AB thymoma **(C37.9)** | **(\*)** |
| New term | 8583/3 | Type B1 thymoma **(C37.9)** | **(\*)** |
| New term | 8584/3 | Type B2 thymoma **(C37.9)** | **(\*)** |
| New term | 8585/3 | Type B3 thymoma **(C37.9)**  Thymoma, atypical **(C37.9)**  Thymoma, epithelial **(C37.9)** | **(\*)** |
| New Pref term | 8693/3 | Paraganglioma | **(\*)** |
| New term | 8700/3 | Pheochromocytoma | **(\*)** |

**(\*) prior to 1/1/2021, these histologies were reportable only when the pathologist included “malignant” in the diagnosis term. Example: thymoma, malignant or malignant thymoma. WHO as dropped malignant from the reportable term. All of the neoplasms listed are reportable as /3 unless stated to be benign**

**Table 5: New Terms and ICD-O codes**

|  |  |  |  |
| --- | --- | --- | --- |
| **Action** | **ICD-O**  **Code** | **Term/site** | **Comment** |
| New code/term  Synonym | 8273/3 | Pituitary blastoma  Embryoma |  |
| New code/term | 9749/3 | Erdhiem-Chester Disease |  |
| New code/term | 9766/3 | Lymphomatoid granulomatosis, grade 3 |  |
| New code/term | 9819/3 | B-lymphocytic leukemia/lymphoma, BCR-ABL1-like |  |
| New code/term | 9877/3 | Acute myeloid leukemia with mutated NPM1 |  |
| New code/term | 9878/3 | Acute myeloid leukemia with biallelic mutations of CEBPA |  |
| New code/term | 9879/3 | Acute myeloid leukemia with mutated RUNX1 |  |
| New code/term | 9912/3 | Acute myeloid leukemia with BCR-ABL1 |  |
| New code/term | 9968/3 | Myeloid/lymphoid neoplasms with PCM1-JAK2 |  |
| New code/term | 9993/3 | Myelodysplastic syndrome with ring sideroblasts and multilineage dysplasia |  |
| New code/term | 9715/3 | Anaplastic large cell lymphoma ALK-negative Breast implant-associated anaplastic large cell lymphoma |  |
| New code/term | 8349/1 | Non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) C73.9)  Non-invasive FTP (C73.9) | **This term was previously coded to 8343/2. The new code and behavior will make this non-reportable** |